Innoviva to Report Third Quarter 2016 Financial Results on October 27 at 5:00 p.m. EDT
October 19 2016 - 4:05PM
Business Wire
Innoviva, Inc. (NASDAQ: INVA) announced today that it will
report financial results for the third quarter ended September 30,
2016 after market close on Thursday, October 27, 2016. Innoviva
management will host a webcast and conference call at 5:00 p.m. EDT
that day to discuss the financial results and provide a corporate
update.
To participate in the live call dial (877) 837-3908 from the
U.S., or (973) 890-8166 for international callers and enter
Conference ID: 97037854. A live webcast of the call will be
available at: http://edge.media-server.com/m/p/6stsppn8 or from the
investor relations section of the company website at www.inva.com
and will be archived for 30 days. A telephone replay of the call
will be available through Nov. 3, 2016, by dialing (855) 859-2056
from the U.S., or (404) 537-3406 for international callers and
entering Conference ID: 97037854.
About Innoviva
Innoviva is focused on bringing compelling new medicines to
patients in areas of unmet need by leveraging its significant
expertise in the development, commercialization and financial
management of bio-pharmaceuticals. Innoviva's portfolio is anchored
by the respiratory assets partnered with Glaxo Group Limited (GSK),
including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were
jointly developed by Innoviva and GSK. Under the agreement with
GSK, Innoviva is eligible to receive associated royalty revenues
from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and
commercialized, VI monotherapy, as well. In addition, Innoviva
retains a 15 percent economic interest in future payments made by
GSK for earlier-stage programs partnered with Theravance Biopharma,
Inc. For more information, please visit Innoviva's website at
www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the
GlaxoSmithKline group of companies.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161019005025/en/
Innoviva, Inc.Eric d’EsparbesSenior Vice President and Chief
Financial Officer650-238-9640investor.relations@thrxinc.com
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Apr 2023 to Apr 2024